BACKGROUND: Methamphetamine (MA) use among pregnant women is an increasing problem in the United States. The impact of prenatal MA exposure on development in childhood is unknown. OBJECTIVE: To examine the effects of prenatal MA exposure on motor and cognitive development in children at 1, 2, and 3 years of age. DESIGN/ METHODS: IDEAL enrolled 412 mother-infant pairs at four sites (Tulsa OK, Des Moines IA, Los Angeles CA, and Honolulu HI). MA subjects (n=204) were identified by self report or GC/MS confirmation of amphetamine and metabolites in infant meconium. Comparison subjects (n=208) were matched (race, birth weight, maternal education, and type of insurance), denied amphetamine use, and had a negative meconium screen. Both groups included prenatal alcohol, tobacco and marijuana use, but excluded use of opiates, lysergic acid diethylamide, phencyclidine or cocaine only. The Peabody Developmental Motor Scales (PDMS-2) were administered to the infants at the 1 and 3 year visits. This analysis includes a subsample (n=350) of the IDEAL study with completed 1 and/or 3 year visits (n=330 and 281, respectively). At each annual visit we also conducted the Bayley Scales of Infant Development (BSID-II) as a general evaluation of mental and motor development. The BSID-II analysis includes a subsample (n=356) of the IDEAL study with completed 1, 2, and/or 3 year visits (n=331, 288, and 278 respectively). GLM analysis conducted on the PDMS-2 and BSID-II examined the effects of MA exposure and heavy MA exposure (≥3 days of use/week), with and without covariates. Longitudinal analyses were used to examine the effects of MA exposure on changes in motor and cognitive performance over time. RESULTS: Heavy MA exposure was associated with significantly lower grasping scores than some and no use at 1 year (P=0.018). In longitudinal analysis, lower grasping scores associated with any MA exposure and heavy exposure persisted to 3 years. There were no effects of MA exposure, including heavy exposure, on the Bayley Mental Development Index (MDI) or Psychomotor Development Index (PDI) at any or across age. CONCLUSIONS: There were no differences in cognition as assessed by the BSID-II between the groups. There was a subtle MA exposure effect on fine motor performance at 1 year with the poorest performance observed in the most heavily exposed children. By 3 years, no differences in fine motor performance were observed. These findings suggest MA exposure has modest motor effects at 1 year that are mostly resolved by 3 years. Copyright Â
BACKGROUND:Methamphetamine (MA) use among pregnant women is an increasing problem in the United States. The impact of prenatal MA exposure on development in childhood is unknown. OBJECTIVE: To examine the effects of prenatal MA exposure on motor and cognitive development in children at 1, 2, and 3 years of age. DESIGN/ METHODS: IDEAL enrolled 412 mother-infant pairs at four sites (Tulsa OK, Des Moines IA, Los Angeles CA, and Honolulu HI). MA subjects (n=204) were identified by self report or GC/MS confirmation of amphetamine and metabolites in infant meconium. Comparison subjects (n=208) were matched (race, birth weight, maternal education, and type of insurance), denied amphetamine use, and had a negative meconium screen. Both groups included prenatal alcohol, tobacco and marijuana use, but excluded use of opiates, lysergic acid diethylamide, phencyclidine or cocaine only. The Peabody Developmental Motor Scales (PDMS-2) were administered to the infants at the 1 and 3 year visits. This analysis includes a subsample (n=350) of the IDEAL study with completed 1 and/or 3 year visits (n=330 and 281, respectively). At each annual visit we also conducted the Bayley Scales of Infant Development (BSID-II) as a general evaluation of mental and motor development. The BSID-II analysis includes a subsample (n=356) of the IDEAL study with completed 1, 2, and/or 3 year visits (n=331, 288, and 278 respectively). GLM analysis conducted on the PDMS-2 and BSID-II examined the effects of MA exposure and heavy MA exposure (≥3 days of use/week), with and without covariates. Longitudinal analyses were used to examine the effects of MA exposure on changes in motor and cognitive performance over time. RESULTS: Heavy MA exposure was associated with significantly lower grasping scores than some and no use at 1 year (P=0.018). In longitudinal analysis, lower grasping scores associated with any MA exposure and heavy exposure persisted to 3 years. There were no effects of MA exposure, including heavy exposure, on the Bayley Mental Development Index (MDI) or Psychomotor Development Index (PDI) at any or across age. CONCLUSIONS: There were no differences in cognition as assessed by the BSID-II between the groups. There was a subtle MA exposure effect on fine motor performance at 1 year with the poorest performance observed in the most heavily exposed children. By 3 years, no differences in fine motor performance were observed. These findings suggest MA exposure has modest motor effects at 1 year that are mostly resolved by 3 years. Copyright Â
Authors: Daniel S Messinger; Charles R Bauer; Abhik Das; Ron Seifer; Barry M Lester; Linda L Lagasse; Linda L Wright; Seetha Shankaran; Henrietta S Bada; Vincent L Smeriglio; John C Langer; Marjorie Beeghly; W Kenneth Poole Journal: Pediatrics Date: 2004-06 Impact factor: 7.124
Authors: Michael T Williams; Tracy L Blankenmeyer; Tori L Schaefer; Carrie A Brown; Gary A Gudelsky; Charles V Vorhees Journal: Brain Res Dev Brain Res Date: 2003-12-30
Authors: Maja A Kwiatkowski; Annerine Roos; Dan J Stein; Kevin G F Thomas; Kirsty Donald Journal: Metab Brain Dis Date: 2013-12-28 Impact factor: 3.584
Authors: Trecia A Wouldes; Linda L Lagasse; Marilyn A Huestis; Sheri Dellagrotta; Lynne M Dansereau; Barry M Lester Journal: Neurotoxicol Teratol Date: 2014-02-22 Impact factor: 3.763
Authors: Chris Derauf; Linda L Lagasse; Lynne M Smith; Elana Newman; Rizwan Shah; Charles R Neal; Amelia M Arria; Marilyn A Huestis; Sheri Dellagrotta; Lynne M Dansereau; Hai Lin; Barry M Lester Journal: J Pediatr Date: 2012-03-15 Impact factor: 4.406
Authors: Sabrina D Diaz; Lynne M Smith; Linda L LaGasse; Chris Derauf; Elana Newman; Rizwan Shah; Amelia Arria; Marilyn A Huestis; Sheri Della Grotta; Lynne M Dansereau; Charles Neal; Barry M Lester Journal: J Pediatr Date: 2014-03-12 Impact factor: 4.406
Authors: Lynn T Singer; Derek G Moore; Sarah Fulton; Julia Goodwin; John J D Turner; Meeyoung O Min; Andrew C Parrott Journal: Neurotoxicol Teratol Date: 2012-03-03 Impact factor: 3.763
Authors: Namik Kirlic; Elana Newman; Linda L Lagasse; Chris Derauf; Rizwan Shah; Lynne M Smith; Amelia M Arria; Marilyn A Huestis; William Haning; Arthur Strauss; Sheri Dellagrotta; Lynne M Dansereau; Beau Abar; Charles R Neal; Barry M Lester Journal: J Stud Alcohol Drugs Date: 2013-05 Impact factor: 2.582
Authors: Chris Derauf; Barry M Lester; Nurunisa Neyzi; Minal Kekatpure; Luis Gracia; James Davis; Kalpana Kallianpur; Jimmy T Efird; Barry Kosofsky Journal: Dev Neurosci Date: 2012-08-17 Impact factor: 2.984
Authors: Beau Abar; Linda L LaGasse; Chris Derauf; Elana Newman; Rizwan Shah; Lynne M Smith; Amelia Arria; Marilyn Huestis; Sheri Della Grotta; Lynne M Dansereau; Charles Neal; Barry M Lester Journal: Psychol Addict Behav Date: 2012-10-15